Results - Announcements
Gland Pharma Ltd share price inched up 0.70% to Rs 3169.4 after the company's net profit eased 8.27% to Rs 290.76 crore, while revenue from operations improved marginally 1.85% to Rs 1833.59 crore in Q2FY27 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.82 lakh crore, easing 5.54%. It has improved by 2.89% over last one week and crept higher by 3.43% in last one month while the market capitalization of Gland Pharma Ltd has marginally improved by 2.32% and 21.91% in the same period respectively.
Profit before tax (PBT) of Gland Pharma Ltd stood at Rs 430.94 crore in Q2 FY27, expanding by 51.78% year-on-year, and declining 0.93% quarter-on-quarter. EBITDA came in at Rs 415 crore, surging by 80.64% YoY and slipping 3.07% sequentially.
Total expenses grew marginally by 2.98% to Rs 1464.56 crore in Q2FY27 over Q2FY26. During the quarter, cost of materials consumed stood at Rs 640.75 crore, inching up 8.93% YoY, while employee benefits expense was at Rs 411.51 crore, dropping 7.32% YoY.
For FY26, revenue from operations rose 14.50% to Rs 6430.65 crore, while net profit saw a strong growth of 47.07% to Rs 1027.32 crore, compared to previous FY. EBITDA soared by 110011% to Rs 1313.22 crore, and PBT witnessed a strong rise of 37.82% to Rs 1464.58 crore compared to previous FY.
The company's consolidated net cash flow from operating activities stood at Rs 1031.39 crore in FY26, as against Rs 914.73 crore in FY25.
Gland Pharma Ltd rallied 66.94% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 2.74% during the same period.